Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aila (also known as Aila tablets) is a botanical drug candidate developed by the Xinjiang Institute of Ecology and Geography of the Chinese Academy of Sciences for the treatment of erectile dysfunction (ED). Derived from traditional Uighur medicine, the drug is primarily composed of extracts from the seeds of *Allium cepa* (onion). It is formulated as a standardized tablet and is intended to address male sexual dysfunction, often referred to in clinical contexts as male weakness. Aila is currently undergoing Phase II clinical trials in China (e.g., CTR20243011) to evaluate its therapeutic efficacy and safety profile in patients with erectile dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aila.